Teachers Retirement System of The State of Kentucky Sells 23,732 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Teachers Retirement System of The State of Kentucky cut its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 11.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 183,392 shares of the company's stock after selling 23,732 shares during the quarter. Teachers Retirement System of The State of Kentucky owned approximately 0.13% of Denali Therapeutics worth $2,494,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Denali Therapeutics by 7.6% in the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock worth $244,993,000 after buying an additional 843,996 shares during the period. FMR LLC lifted its holdings in shares of Denali Therapeutics by 2.4% during the fourth quarter. FMR LLC now owns 8,019,746 shares of the company's stock valued at $163,442,000 after purchasing an additional 188,368 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Denali Therapeutics by 8.8% during the fourth quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company's stock valued at $67,573,000 after purchasing an additional 268,378 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Denali Therapeutics by 6.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,058,615 shares of the company's stock valued at $62,335,000 after purchasing an additional 188,820 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Denali Therapeutics by 19.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company's stock valued at $37,805,000 after purchasing an additional 295,594 shares during the last quarter. 92.92% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Denali Therapeutics news, CEO Ryan J. Watts sold 495,282 shares of Denali Therapeutics stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total value of $7,429,230.00. Following the completion of the sale, the chief executive officer owned 253,071 shares of the company's stock, valued at approximately $3,796,065. The trade was a 66.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 12.50% of the company's stock.

Denali Therapeutics Trading Down 4.5%

NASDAQ:DNLI traded down $0.64 during trading hours on Friday, reaching $13.67. The company had a trading volume of 1,178,092 shares, compared to its average volume of 1,494,712. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -5.12 and a beta of 1.33. The firm's 50 day moving average price is $14.22 and its 200-day moving average price is $16.12.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period last year, the company earned ($0.68) EPS. On average, analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. Robert W. Baird lowered their target price on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Bank of America lowered their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a report on Monday, May 19th. Cantor Fitzgerald upgraded shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. Finally, Wedbush lowered their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $33.71.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.